CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company…